Inspire Medical Systems, Inc.
Inspire Medical Systems Reports Strong Q3 2024 Results and Raises Guidance
Summary
Inspire Medical Systems, Inc. reported its third-quarter 2024 financial results, highlighting year-over-year revenue growth of 33% to $203.2 million and earnings per share of $0.60. The company also announced it activated 66 new U.S. centers and created 13 new U.S. sales territories. Further, it received FDA approval of the Inspire V neurostimulation system. Management raised full-year revenue guidance to $793 million to $798 million and diluted net income per share guidance to $1.20 to $1.40.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement